Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Processa Pharmaceuticals, Inc. (PCSA)

Processa appoints Gregory Flesher as chief operating officer, effective November 4, 2026

Neutral Impact 3 of 5 leadership Written later

Processa Pharmaceuticals appointed Gregory J. Flesher as Chief Operating Officer, effective November 4, 2026, under an employment letter with a $700,000 annual base salary. The filing also discloses compensation for non-employee executive chair Dr. Sheila Gujrathi, and both executives' planned option grants depend on stockholder approval of the 2027 Equity Incentive Plan.

Key points

  • Flesher: $700,000 annual base salary and a discretionary target bonus of up to 60% of base salary beginning in fiscal 2027.
  • Planned option grant to Flesher equal to 3.0% of fully-diluted outstanding capital stock, contingent on stockholder approval of the 2027 Equity Incentive Plan at the Conversion Special Meeting.
  • Dr. Sheila Gujrathi, non-employee executive chair: $300,000 annual base compensation and a planned option grant equal to 1.5% of fully-diluted outstanding capital stock.
  • A November 4, 2026 press release announced Flesher's appointment and other leadership appointments.

The filing

CompanyProcessa Pharmaceuticals, Inc. (PCSA)
Form8-K, current report
Filed with the SECNov 4, 2026, 8:10 AM ET
Accession number0001140361-26-041901

Items reported: 5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.